Prospective, Randomized, Single-blind Comparison of Effects of 6 months' Treatment with Atorvastatin Versus Pravastatin on Leptin and Angiogenic Factors in Patients with Coronary Artery Disease

Overview

Journal Heart Vessels

Specialty Cardiology & Vascular Diseases

Date 2011 Jun 7

PMID 21643812

Citations 15

Authors

Yuji Takahashi

Mamoru Satoh

Tsuyoshi Tabuchi

Motoyuki Nakamura

Affiliations

Soon will be listed here.

Abstract

Leptin has been reported to exert an atherosclerotic effect by regulating expression of angiogenic factors that have been implicated in the pathogenesis of coronary artery disease (CAD). The purpose of this study was to investigate whether lipid-lowering therapy (LLT) with statins could affect leptin levels and angiogenic factors in patients with CAD. This study included 76 patients with CAD and 15 subjects without CAD (non-CAD). CAD patients were randomized to 6 months of intensive LLT with atorvastatin or moderate LLT with pravastatin. Plasma leptin, angiopoetin-2 (Ang-2), hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) levels were measured prior to statin therapy (baseline) and after 6 months. Baseline levels of leptin, Ang-2, HGF and VEGF were higher in the CAD group than in the non-CAD group (all P < 0.05). Treatment with intensive LLT decreased leptin, Ang-2, HGF and VEGF levels, whereas moderate LLT did not change these levels. This study suggests that LLT with atorvastatin decreases leptin levels and angiogenic factors in patients with CAD, possibly contributing to the beneficial effects of LLT with atorvastatin in CAD.

Citing Articles

Cardiac rehabilitation may influence leptin and VEGF A crosstalk in patients after acute coronary syndrome.

Skrypnik D, Skrypnik K, Suliburska J, Bogdanski P Sci Rep. 2022; 12(1):11825.

PMID: 35821400 PMC: 9276756. DOI: 10.1038/s41598-022-16053-1.

New Insights on the Relationship between Leptin, Ghrelin, and Leptin/Ghrelin Ratio Enforced by Body Mass Index in Obesity and Diabetes.

Sitar-Taut A, Cozma A, Fodor A, Coste S, Orasan O, Negrean V Biomedicines. 2021; 9(11).

PMID: 34829886 PMC: 8615809. DOI: 10.3390/biomedicines9111657.

Novel Therapeutical Approaches to Managing Atherosclerotic Risk.

Giglio R, Pantea Stoian A, Al-Rasadi K, Banach M, Patti A, Ciaccio M Int J Mol Sci. 2021; 22(9).

PMID: 33924893 PMC: 8125277. DOI: 10.3390/ijms22094633.

Effect of high fat diet and excessive compressive mechanical force on pathologic changes of temporomandibular joint.

Du J, Jiang Q, Mei L, Yang R, Wen J, Lin S Sci Rep. 2020; 10(1):17457.

PMID: 33060739 PMC: 7566592. DOI: 10.1038/s41598-020-74326-z.

Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review.

Kaluzna M, Trzeciak I, Ziemnicka K, Machaczka M, Ruchala M Orphanet J Rare Dis. 2019; 14(1):275.

PMID: 31791361 PMC: 6889605. DOI: 10.1186/s13023-019-1211-5.

References

Shamsuzzaman A, Winnicki M, Wolk R, Svatikova A, Phillips B, Davison D . Independent association between plasma leptin and C-reactive protein in healthy humans. Circulation. 2004; 109(18):2181-5. DOI: 10.1161/01.CIR.0000127960.28627.75. View

Wallerstedt S, Eriksson A, Niklason A, Ohlsson C, Hedner T . Serum leptin and myocardial infarction in hypertension. Blood Press. 2004; 13(4):243-6. DOI: 10.1080/08037050410021405. View

Nissen S, Tuzcu E, Schoenhagen P, Brown B, Ganz P, Vogel R . Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004; 291(9):1071-80. DOI: 10.1001/jama.291.9.1071. View

Cao R, Brakenhielm E, Wahlestedt C, Thyberg J, Cao Y . Leptin induces vascular permeability and synergistically stimulates angiogenesis with FGF-2 and VEGF. Proc Natl Acad Sci U S A. 2001; 98(11):6390-5. PMC: 33478. DOI: 10.1073/pnas.101564798. View

von Eynatten M, Schneider J, Hadziselimovic S, Hamann A, Bierhaus A, Nawroth P . Adipocytokines as a novel target for the anti-inflammatory effect of atorvastatin in patients with type 2 diabetes. Diabetes Care. 2005; 28(3):754-5. DOI: 10.2337/diacare.28.3.754. View

Park H, Kwon H, Lim H, Hong B, Lee J, Park B . Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med. 2001; 33(2):95-102. DOI: 10.1038/emm.2001.17. View

FRIEDEWALD W, Levy R, Fredrickson D . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18(6):499-502. View

Nath A, Murakami C, Garcia-Cardena G, Papapetropoulos A, Sessa W, Madge L . Biological action of leptin as an angiogenic factor. Science. 1998; 281(5383):1683-6. DOI: 10.1126/science.281.5383.1683. View

Woods A, Stock M . Leptin activation in hypothalamus. Nature. 1996; 381(6585):745. DOI: 10.1038/381745a0. View

10.

Mavri A, Poredos P, Suran D, Gaborit B, Juhan-Vague I, Poredos P . Effect of diet-induced weight loss on endothelial dysfunction: early improvement after the first week of dieting. Heart Vessels. 2010; 26(1):31-8. DOI: 10.1007/s00380-010-0016-1. View

11.

Peelman F, Waelput W, Iserentant H, Lavens D, Eyckerman S, Zabeau L . Leptin: linking adipocyte metabolism with cardiovascular and autoimmune diseases. Prog Lipid Res. 2004; 43(4):283-301. DOI: 10.1016/j.plipres.2004.03.001. View

12.

Davignon J . Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004; 109(23 Suppl 1):III39-43. DOI: 10.1161/01.CIR.0000131517.20177.5a. View

13.

Oka H, Ikeda S, Koga S, Miyahara Y, Kohno S . Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases. Heart Vessels. 2008; 23(4):249-56. DOI: 10.1007/s00380-008-1038-9. View

14.

Cao Y . Angiogenesis modulates adipogenesis and obesity. J Clin Invest. 2007; 117(9):2362-8. PMC: 1963348. DOI: 10.1172/JCI32239. View

15.

La Cava A, Matarese G . The weight of leptin in immunity. Nat Rev Immunol. 2004; 4(5):371-9. DOI: 10.1038/nri1350. View

16.

Singhal A, Farooqi I, Cole T, ORahilly S, Fewtrell M, Kattenhorn M . Influence of leptin on arterial distensibility: a novel link between obesity and cardiovascular disease?. Circulation. 2002; 106(15):1919-24. DOI: 10.1161/01.cir.0000033219.24717.52. View

17.

Soderberg S, Ahren B, Jansson J, Johnson O, Hallmans G, Asplund K . Leptin is associated with increased risk of myocardial infarction. J Intern Med. 1999; 246(4):409-18. DOI: 10.1046/j.1365-2796.1999.00571.x. View

18.

Soderberg S, Colquhoun D, Keech A, Yallop J, Barnes E, Pollicino C . Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study. Int J Obes (Lond). 2008; 33(1):123-30. DOI: 10.1038/ijo.2008.224. View

19.

Beltowski J . Leptin and atherosclerosis. Atherosclerosis. 2006; 189(1):47-60. DOI: 10.1016/j.atherosclerosis.2006.03.003. View

20.

Wallace A, McMahon A, Packard C, Kelly A, Shepherd J, Gaw A . Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation. 2001; 104(25):3052-6. DOI: 10.1161/hc5001.101061. View